All News

7 December 2009

Nplate(R) Data From MDS Studies Presented at ASHAntibodies

7 December 2009

Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry DayAntibodies

7 December 2009

Seattle Genetics Reports Positive Data from Phase I Weekly-Dosing Clinical Trial of Brentuximab Vedotin (SGN-35) in LymphomaAntibodies

7 December 2009

ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Multiple MyelomaAntibodies

7 December 2009

PharmAthene Presents Phase I Clinical Trial Results and New Therapeutic Animal Model Data for Protexia(R)Antibodies

4 December 2009

Biotest AG: European Commission grants approval of Zutectra(R)Antibodies

4 December 2009

Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron PharmaAntibodies

3 December 2009

Kyto Biopharma Inc. Announces High-Affinity Monoclonal Antibody to the Cellular Receptor for Transcobalamin (Vitamin B12)Antibodies

3 December 2009

Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller UniversityAntibodies

2 December 2009

Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer TrialAntibodies

1 December 2009

Trellis Bioscience Grants MedImmune License for Its Anti-RSV AntibodiesAntibodies

1 December 2009

Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapyAntibodies

30 November 2009

Xencor Licenses Antibody Optimization TechnologyAntibodies

24 November 2009

Seattle Genetics and Agensys, an Affiliate of Astellas, Expand Antibody-Drug Conjugate CollaborationAntibodies

23 November 2009

GLYCOTOPE receives regulatory approval for GlycoExpress Technology and initiates first clinical trial with lead antibody GT-MAB 2.5 GEXAntibodies

23 November 2009

Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic EsophagitisAntibodies

20 November 2009

ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company’s TAP TechnologyAntibodies

20 November 2009

ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)Antibodies

19 November 2009

Merck KGaA: CHMP Opinion for Erbitux in Advanced Non-Small Cell Lung CancerAntibodies

18 November 2009

Genentech and Biogen Idec Receive a Complete Response from the FDA for Rituxan for Chronic Lymphocytic LeukemiaAntibodies

18 November 2009

Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID® combined with anti-kir antibody IPH 2101 in patients with multiple myelomaAntibodies

17 November 2009

ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell CarcinomaAntibodies

17 November 2009

HUMAN GENOME SCIENCES RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR RAXIBACUMAB BIOLOGICS LICENSE APPLICATIONAntibodies

17 November 2009

Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast CancerAntibodies

17 November 2009

Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75Antibodies

16 November 2009

BioInvent and ThromboGenics Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients with Advanced Solid TumoursAntibodies

16 November 2009

Human Genome Sciences Receives Complete Response Letter from FDA for Raxibacumab Biologics License ApplicationAntibodies

13 November 2009

BioInvent signs licensing agreement with Daiichi Sankyo for the discovery and development of therapeutic antibodiesAntibodies

12 November 2009

Abbott to Acquire Novel Investigational Biologic to Treat Chronic PainAntibodies

11 November 2009

Sanofi-aventis and Regeneron expand strategic Antibody CollaborationAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Report Package: Bispecific Antibodies

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

PD-1 Agonists Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Her3-Targeted Immunotherapy Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing